FDA Determines Regulatory Review Period for Risperdal Patent Extension

Summary

The Food and Drug Administration has published a notice determining the regulatory review period for Risperdal, a human drug product, in response to a patent extension application submitted to the Commissioner of Patents and Trademarks.